Eurofins Technologies announces the launch of two RT-PCR assays to accurately diagnose respiratory diseases caused by SARS-CoV-2, Influenza virus or RSV. Since initial symptoms produced by these pathogens are indistinguishable, access to accurate and reliable tests will help clinicians improve patient care.

These new CE-marked multiplex kits have been specifically designed to detect and differentiate three viral infections in the same PCR run. The Mplex SARS-CoV-2+, Flu A, Flu B (C1) RT-PCR assay facilitates differentiation, in a single reaction, between Influenza A, B, and SARS-CoV-2, with simultaneous detection of two SARS-CoV-2 targets (N-gene + RdRP gene) as recommended by the WHO¹. The RSV A, RSV B RT-PCR assay can differentiate between respiratory syncytial virus A and B.

Both kits can be processed in parallel on the same plate, using the same temperature profile, and provide results in approximately 1 hour. An internal control (RNaseP) is included for adequate sample processing, and to monitor RNA extraction and the presence of potential inhibitors in the RT-PCR reaction. The AriaDx^TM and AriaMx^TM thermocyclers from Agilent Technologies are validated for both assays. ABI Prism^® 7500 Fast SDS and QuantStudio^TM 5 from Applied Biosystems™, CFX96 Touch™ from Bio-Rad, and LightCycler^® 480 II from Roche are validated for the RSV A, RSV B RT-PCR kit.

Co-circulation of respiratory tract viruses during the COVID-19 pandemic poses unprecedented challenges to healthcare systems worldwide, and Eurofins Technologies endeavours to continue to provide high quality solutions for multi-pathogen testing.

¹ World Health Organization. (2020). Diagnostic testing for SARS-CoV-2: interim guidance, 11 September 2020. World Health Organization. https://apps.who.int/iris/handle/10665/334254.

For more information, please visit Eurofins Technologies website.

About Eurofins Technologies – a fast growing provider of diagnostic technologies in the field of immunoassays and molecular detection methods

Building on the experience and scientific excellence of the Eurofins Group, Eurofins Technologies is a fast growing global provider of diagnostic technologies and industry-leading ELISA-based instruments in the field of bioanalytical testing for the food, feed, environmental, animal health, and clinical diagnostics industries.

About Eurofins – the global leader in bio-analysis

Eurofins is Testing for Life. With 55,000 staff across a network of 900 laboratories in over 50 countries, Eurofins’ companies offer a portfolio of over 200,000 analytical methods.

Eurofins Shares are listed on Euronext Paris Stock Exchange.

View source version on businesswire.com: https://www.businesswire.com/news/home/20211201005406/en/